Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study

Acute Cardiac Care

Volumn 10, Issue 2, 2008, Pages 93-99

  De Luca, Leonardo ^a   Sardella, Gennaro ^b   De Persio, Giovanni ^a   Petrolini, Alessandro ^a   Fedele, Francesco ^b  

^a EUROPEAN HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Abciximab; Diabetes mellitus; Drug eluting stent; GP IIb IIIa blockade; Restenosis

Indexed keywords

ABCIXIMAB; PACLITAXEL; PLACEBO;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; STENTS; SURGICAL PROCEDURES, ELECTIVE; TREATMENT OUTCOME;

EID: 45849100862     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/17482940701747063     Document Type: Article

References (33)

1. van Domburg RT, Lemos PA, Takkenberg JJ, van Domburg RT, Lemos PA, Takkenberg JJ, et al. The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease. Eur Heart J. 2005;26:675-81.
2. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology. Drug-eluting stents: Part I. Circulation. 2003;107:2274-9.
3. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology. Drug-eluting stents: Part II. Circulation. 2003;107:2383-9.
4. O'Neill WW, Leon MB. Drug-eluting stents. Costs versus clinical benefit. Circulation. 2003;107:3008-11.
5. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-94.
6. Serruys PW, Degertekin M, Tanabe K, Russell ME, Guagliumi G, Webb J, et al. TAXUS II Study Group. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation. 2004;109:627-33.
7. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003;107:559-64.
8. Stone GW, Ellis S, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A Polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-31.
9. Stone GW, Ellis S, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS Stent. The TAXUS-IV trial. Circulation. 2004;109:1942-7.
10. Finn AV, Gold HK. One year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent in patients with diabetes mellitus. Circulation. 2004;110:e318-9.
11. Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, et al. for the Intracoronary Stenting and Antithrombotic Regimen: Is abciximab a superior way to eliminate elevated thrombotic risk in diabetics (ISAR-SWEET) study investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation. 2004;110:3627-35.
12. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. Ann Intern Med. 1991;115:256-65.
13. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al. for the ISAR-DIABETES study investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353:663-70.
14. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. the multivessel angioplasty prognosis study group. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation. 1990;82:1193-202.
15. King SB, Mahmud E. Will blocking the platelet save the diabetic? Circulation. 1999;100:2466-8.
16. Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists. The diabetic patient. Rev Cardiovasc Med. 2002;3:S20-7.
17. Lincoff AM. Important triad in cardiovascular medicine. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation. 2003;107:1556-9.
18. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, Rosenthal ML, Godfrey NK, Coller BS et al. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients untergoing percutaneous coronary intervention. Circulation 1999;100:1977-82.
19. Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, et al. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol. 2005;95:1-7.
20. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922-8.
21. De Luca L, De Persio G, Minati M, Iacoboni C, Fedele F. Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting. Am Heart J. 2005;149:e11-8.
22. Teirstein PS, Kao J,Watkins M, Tannenbaum MA, Laufer N, Chang M, et al. Impact of platelet glycoprotein IIb/IIIa inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy). Am J Cardiol. 2005;96:500-5.
23. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999;100:799-806.
24. Müller I, Seyfarth M, Rüdiger S, Wolf B, Pogatsa-Murray G, Schomig A, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001;85:92-3.
25. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004;350:232-8.
26. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 2001;104:163-7.
27. Kereiakes DJ. Inflammation as a therapeutic target: a unique role for abciximab. Am Heart J. 2003;146:S1-4.
28. Tang WWH, Lincoff AM. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade. The triad revisited. Circulation. 2004;110:3618-20.
29. Finn AV, Palacios IF, Kastrati A, Gold HK. Drug-eluting stents for diabetes mellitus. A rush to judgment? J Am Coll Cardiol. 2005;45:479-83.
30. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-80.
31. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus eluting stents versus standard stents in patients with stenosis in native coronary artery. N Engl J Med. 2003;349:1315-23.
32. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx (velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004;109:2273-8.
33. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd et al.; American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:e166-286.